Endo's got a deal for Auxilium Pharmaceuticals in mind. CEO Rajiv De Silva thinks it could be a home run, and analysts seem to agree. Auxilium, however, needs some time to think it over, and it's swallowed a poison pill to make sure it gets just that.
In its latest product acquisition, Integra LifeSciences is buying instrumentation lines from Medtronic for $60 million in cash. These include about 4,000 MicroFrance and Xomed manual ENT and laparoscopic surgical instruments. The surgical products company will also gain a manufacturing facility in St. Aubin le Monial, France.
Just a few days after Auxilium Pharmaceuticals put out the word that pressure on the sales side was forcing a restructuring and the elimination of about 200 jobs, Endo has come along with a proposal to buy out the company for about $2.2 billion worth of cash and stock.
After months of battling between Allergan and its pursuers, Valeant and Pershing Square Capital Management, the two sides have reached a truce--at least when it comes to an upcoming shareholder meeting.
Remember all those industrial and investment promises Pfizer made when it was trying to snag AstraZeneca earlier this year? The body that polices U.K. dealmaking is eyeing new rules that would give it more power to enforce such promises, should Pfizer--or another company--come calling in the future.
Medtronic launched the wireless, adhesive heart monitor that it acquired when it bought startup Corventis in June reportedly for more than $150 million. The monitor can be worn up to 30 days to detect and diagnose the cause of irregular heartbeats. But the device remains a second-line tool behind the bulky Holter monitor.
A long-anticipated acquisition of Nobel Biocare is now officially in the works as Danaher said it would acquire the dental company for about $2.2 billion. The deal is expected to make Danaher the market leader in dental equipment and consumables.
The threat of action from lawmakers may have put a damper on pharma's tax inversion frenzy, but it has not stopped the wave of deals that are taking American drugmakers overseas. Next up could be Illinois' Akorn, which is reportedly looking into a bid for Belgian pharma UCB's U.S. subsidiary.
Kimberly-Clark's spinoff of its $1.6 billion healthcare business is scheduled to occur Nov. 1, with the launch of newly independent company Halyard Health.
Allergan had hoped that a lawsuit could potentially prevent Valeant's takeover partner--Bill Ackman, whose Pershing Square Capital Management is Allergan's leading shareholder--from contributing to the 25% investor support threshold needed to call a special meeting. But now, Reuters ' sources say, Team Valeant has rallied support from shareholders holding 35% of the company.